Mar 06, 2026
Summary Iovance’s AMTAGVI has become the first personalized TIL therapy to receive regulatory clearance, gaining accelerated FDA approval for use in advanced melanoma following PD-1 inhibitor treatment. AMTAGVI approval has sparked intensified activity across the field, with companies such as Obsidian Therap...
Read More...
Understanding Bone Densitometers: Technology, Applications, and Impact on Bone Health
Nov 04, 2025
Wireless Brain Sensors: Revolutionizing Neuroscience and Healthcare
Oct 28, 2025
Discover How Learning Disability Treatment Landscape is Evolving with the Emergence of Digital Assistant Technologies
Jul 04, 2025
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper